ALNY Description — Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference (RNAi). RNAi is a biological pathway within cells for sequence-specific silencing and regulation of gene expression. Co. has two RNAi-based medicines, ONPATTRO® (patisiran) and GIVLAARI® (givosiran). ONPATTRO is approved by the United States Food and Drug Administration (FDA) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and has also been approved in the European Union, Japan, Canada and Switzerland. GIVLAARI is approved by FDA for the treatment of adults with acute hepatic porphyria.

Company Name: 
Alnylam Pharmaceuticals Inc
Drugs & Pharmaceuticals
Number of ETFs Holding ALNY: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
 ETF   ALNY Weight   ALNY Amount 
 VTI   0.05%   $628,806,493         
 VO   0.31%   $498,400,987         
 VXF   0.28%   $321,505,026         
 IBB   1.58%   $176,394,948         
 VUG   0.10%   $172,507,420         
 VOT   0.59%   $144,326,713         
 IWP   0.53%   $86,455,457         
 IWF   0.10%   $74,017,067         
 VHT   0.36%   $69,623,045         
 FBT   3.40%   $64,844,806         
List of all 60 ETFs holding ALNY »
Quotes delayed 20 minutes

Buy (3.03 out of 4)
27th percentile
(ranked lower than approx. 73% of all stocks covered)

Analysts Forecast:
ALNY Price Target

Based on data provided by Zacks Investment Research via

ETFs Holding ALNY | Alnylam Pharmaceuticals Inc | ETF Channel |

Copyright © 2010 - 2021, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.